中国骨质疏松杂志
中國骨質疏鬆雜誌
중국골질소송잡지
CHINESE JOURNAL OF OSTEOPOROSIS
2014年
1期
22-25
,共4页
杜春莹%胡肇衡%陈玲%段俊红
杜春瑩%鬍肇衡%陳玲%段俊紅
두춘형%호조형%진령%단준홍
双膦酸盐%绝经后骨质疏松症%骨转换指标%骨特异性碱性磷酸酶(BAP)%抗酒石酸酸性磷酸酶(TRAP-5b)
雙膦痠鹽%絕經後骨質疏鬆癥%骨轉換指標%骨特異性堿性燐痠酶(BAP)%抗酒石痠痠性燐痠酶(TRAP-5b)
쌍련산염%절경후골질소송증%골전환지표%골특이성감성린산매(BAP)%항주석산산성린산매(TRAP-5b)
Bisphosphonate%Postmenopausal osteoporosis%Bone turnover biomarkers%Bone specific alkaline phosphatase (BAP)%Tartaric-resistant acid phosphatase(TRAP-5b)
目的：观察抗骨吸收药物双膦酸盐对绝经后骨质疏松症患者骨代谢状态的影响。方法本研究为回顾性研究，共收集在我院骨质疏松门诊数据库中临床资料完整的女性绝经后骨质疏松症患者152例，其中阿仑膦酸钠治疗组93例（A组），每周给予阿仑膦酸钠70mg，一次口服；未服用阿仑膦酸钠对照组59例（B组）。分别观察治疗前和治疗后3、6、12个月骨转换生化指标：骨特异性碱性磷酸酶（BAP）、抗酒石酸酸性磷酸酶（TRAP-5b）及25羟维生素D（25（OH）VD）的变化。结果A组患者经阿仑膦酸钠治疗3个月后BAP和TRAP-5b水平分别较治疗前下降30.60％和32.95％（P＜0.001）治疗6个月时完全降至女性绝经前水平，并一直维持在此水平至治疗后12个月。B组患者治疗前后BAP和TRAP-5b水平差异无统计学意义。结论绝经后骨质疏松症患者骨代谢处于高转换状态，其BAP及TRAP-5b水平较绝经前明显升高；经阿仑膦酸钠治疗3个月后高转换状态可以明显改善，骨转换指标BAP和TRAP-5b水平回落到绝经前水平。
目的：觀察抗骨吸收藥物雙膦痠鹽對絕經後骨質疏鬆癥患者骨代謝狀態的影響。方法本研究為迴顧性研究，共收集在我院骨質疏鬆門診數據庫中臨床資料完整的女性絕經後骨質疏鬆癥患者152例，其中阿崙膦痠鈉治療組93例（A組），每週給予阿崙膦痠鈉70mg，一次口服；未服用阿崙膦痠鈉對照組59例（B組）。分彆觀察治療前和治療後3、6、12箇月骨轉換生化指標：骨特異性堿性燐痠酶（BAP）、抗酒石痠痠性燐痠酶（TRAP-5b）及25羥維生素D（25（OH）VD）的變化。結果A組患者經阿崙膦痠鈉治療3箇月後BAP和TRAP-5b水平分彆較治療前下降30.60％和32.95％（P＜0.001）治療6箇月時完全降至女性絕經前水平，併一直維持在此水平至治療後12箇月。B組患者治療前後BAP和TRAP-5b水平差異無統計學意義。結論絕經後骨質疏鬆癥患者骨代謝處于高轉換狀態，其BAP及TRAP-5b水平較絕經前明顯升高；經阿崙膦痠鈉治療3箇月後高轉換狀態可以明顯改善，骨轉換指標BAP和TRAP-5b水平迴落到絕經前水平。
목적：관찰항골흡수약물쌍련산염대절경후골질소송증환자골대사상태적영향。방법본연구위회고성연구，공수집재아원골질소송문진수거고중림상자료완정적녀성절경후골질소송증환자152례，기중아륜련산납치료조93례（A조），매주급여아륜련산납70mg，일차구복；미복용아륜련산납대조조59례（B조）。분별관찰치료전화치료후3、6、12개월골전환생화지표：골특이성감성린산매（BAP）、항주석산산성린산매（TRAP-5b）급25간유생소D（25（OH）VD）적변화。결과A조환자경아륜련산납치료3개월후BAP화TRAP-5b수평분별교치료전하강30.60％화32.95％（P＜0.001）치료6개월시완전강지녀성절경전수평，병일직유지재차수평지치료후12개월。B조환자치료전후BAP화TRAP-5b수평차이무통계학의의。결론절경후골질소송증환자골대사처우고전환상태，기BAP급TRAP-5b수평교절경전명현승고；경아륜련산납치료3개월후고전환상태가이명현개선，골전환지표BAP화TRAP-5b수평회락도절경전수평。
Objective To observe the effect of bisphosphonates ( Fosamax ) on bone turnover biomarkers in postmenopausal osteoporosis women.Methods A retrospective study was performed.A total of 152 postmenopausal osteoporosis women with complete clinical data, who were selected from the out-patients osteoporosis clinical database of our hospital, were divided into 2 groups:the alendronate treatment group (Group A, n=93) and the control group (Group B, n=59).Patients in Group A took an oral medication of 70mg alendronate tablets ( Fosamax) once a week.And patients in group B were treated without the medication of alendronate.The bone turnover biomarkers, including the changes of bone specific alkaline phosphatase ( BAP) , tartaric-resistant acid phosphatase (TRAP-5b), and 25-hydroxy vitamin D (25(OH)VD), were observed before the treatment and at the 3rd, the 6th, and 12th month after the treatment.Results After 3-month treatment, the serum levels of BAP and TRAP-5b in Group A decreased by 30.60% and 32.95%, respectively, compared with that before the treatment ( P <0.001 ) , And after 6-month treatment, they totally fell back to the level similar to that in premenopausal women, and remained at this level until 12 months after the treatment.On the contrary, no significant difference of the serum levels of BAP and TRAP-5b before and after the treatment in Group B was observed.Conclusion The bone metabolism in postmenopausal osteoporosis patients is at a high turnover status, and the serum levels of BAP and TRAP-5b increased significantly compared to that in premenopausal women.After 3-month treatment with alendronate, the high turnover status can be significantly improved, and the levels of serum BAP and TRAP-5b can fall back to the premenopausal levels.
